Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of BXOS110 for acute ischemic stroke within 3 hours of onset
CTR20260333Phase 3Active
- Sponsor
- Biosyous
- Start
- Feb 2026
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human prourokinase in ischemic stroke, sponsored by Biosyous. Started Feb 2026; status: active.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20260333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260333.